Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.
Fund Twenty8 is no longer open to new investments. Please visit our Access EIS Fund page if you wish to make an investment.
Fund Twenty8 follows the decisions of sophisticated private and professional investors to automatically build you a diversified portfolio of no fewer than 28 EIS-qualifying startups.
The fund’s strategy is based on extensive research conducted by NESTA and Intelligent Partnership, which asked the question: how many startup investments should I have?
The magic number appears to be: no fewer than 28. With this many startups in your portfolio, the study suggests a 95% chance of at least one giving you a return of 10X or more. With this in mind, the fund is targeting a return of over 20% IRR, including up to 30% EIS tax relief.
{% youtube cAyo9Tc2yew %}
{% fullWidth grey--title %}
Fund Twenty8 received an independent review from MJ Hudson Allenbridge, a leading independent investment advisory and investment research group, providing independent advice, due diligence and analytical solutions to help institutional investors make better investment decisions.
This independent review has not been commissioned by SyndicateRoom. It has not been issued or approved by SyndicateRoom. It is not a recommendation to invest and does not constitute advice.
{% button "https://files.syndicateroom.com/fund-docs/f28iv-allenbridgereview.pdf" "Download review" primary %}
{% button "https://files.syndicateroom.com/fund-docs/f28iv-rating-certificate-allenbridge.pdf" "View rating certificate" secondary %}
{% endfullWidth %}
While traditional EIS funds normally invest in just a few companies, covering limited sectors, Fund Twenty8 backs a minimum of 28 per fund, per year, offering truly sector-agnostic diversification.
Having just finished deploying its second fund, Fund Twenty8 has:
{% fullWidth grey--title %}
{% blockquote-img "/images/f28-suraj-rajan.jpg" "Suraj" "Rajan" "Fund Twenty8 investor" %}
I’ve been investing in individual companies and have built up a sizeable portfolio, but I’d not invested in EIS funds until I discovered Fund Twenty8.
The focus on diversification makes a lot of sense to me and I think that using the personal investment decisions of numerous savvy investors to deploy capital is a very clever model.
{% endblockquote-img %}
{% endfullWidth %}
<Award
img="/images/icons/icon-coins.svg"
title=""
content=""
data-buttons='[]'
/>
<Award
img="/images/portfolio.svg"
title=""
content=""
data-buttons='[]'
/>
<Award
img="/images/icons/icon-mountains.svg"
title=""
content=""
data-buttons='[]'
/>
PORTFOLIO BREAKDOWN
By following the investment decisions of some of the savviest private investors, Fund Twenty8 automatically builds you a diversified portfolio of no fewer than 28 EIS-qualifying startups. The portfolio of every iteration of Fund Twenty8 will be added to this page as they finish deploying.
{% youtube rBJYbCV8yJ0 %}
{% fullWidth grey--title %}
Fund Twenty8''s 2017 portfolio consists of 32 investments spanning ten sectors. As our portfolio grows and raises further capital, we look forward to seeing its companies succeed.
{% button https://files.syndicateroom.com/fund-docs/F28-2017-portfolio-6MARCH2019.pdf "Download portfolio brochure" primary %}
<img src="/images/f28-engineering.png" alt="bockatech">
<p><b>Bockatech</b><br/>
ENGINEERING</p>
<img src="/images/f28-engineering.png" alt="interpac">
<p><b>Interpac</b><br/>
ENGINEERING</p>
<img src="/images/f28-environment.png" alt="greenspur">
<p><b>Greenspur Renewables</b><br/>
ENVIRONMENT</p>
<img src="/images/f28-environment.png" alt="naked-energy">
<p><b>Naked Energy</b><br/>
ENVIRONMENT</p>
<img src="/images/f28-marketplaces.png" alt="Pass the Keys">
<p><b>Pass the Keys</b><br/>
MARKETPLACES</p>
<img src="/images/f28-marketplaces.png" alt="pekama">
<p><b>Pekama</b><br/>
MARKETPLACES</p>
<p><b>LuckyTrip</b><br/>
MARKETPLACES</p>
<img src="/images/f28-healthcare.png" alt="ambicare">
<p><b>Ambicare</b><br/>
LIFE SCIENCES</p>
<img src="/images/f28-healthcare.png" alt="arcis biotechnology">
<p><b>Arcis Biotechnology</b><br/>
LIFE SCIENCES</p>
<img src="/images/f28-healthcare.png" alt="cipher surgical">
<p><b>Cipher Surgical</b><br/>
LIFE SCIENCES</p>
<img src="/images/f28-healthcare.png" alt="enterobiotix">
<p><b>EnteroBiotix</b><br/>
LIFE SCIENCES</p>
<img src="/images/f28-healthcare.png" alt="Gemetix Healthcare">
<p><b>Gemetix Healthcare</b><br/>
LIFE SCIENCES</p>
<img src="/images/f28-healthcare.png" alt="Molecular Warehouse">
<p><b>Molecular Warehouse</b><br/>
LIFE SCIENCES</p>
<img src="/images/f28-healthcare.png" alt="MGB Biopharma">
<p><b>MGB Biopharma</b><br/>
LIFE SCIENCES</p>
<img src="/images/f28-healthcare.png" alt="Metrion Biosciences">
<p><b>Metrion Biosciences</b><br/>
LIFE SCIENCES</p>
<img src="/images/f28-healthcare.png" alt="Lightpoint Medical">
<p><b>Lightpoint Medical</b><br/>
LIFE SCIENCES</p>
<img src="/images/f28-healthcare.png" alt="PatientSource">
<p><b>PatientSource</b><br/>
LIFE SCIENCES</p>
<img src="/images/f28-pharma.png" alt="Pertinax Pharma">
<p><b>Pertinax Pharma</b><br/>
LIFE SCIENCES</p>
<img src="/images/f28-media.png" alt="Supapass">
<p><b>Supapass</b><br/>
MEDIA</p>
<img src="/images/f28-media.png" alt="NextUp Comedy">
<p><b>NextUp Comedy</b><br/>
MEDIA</p>
<img src="/images/f28-pharma.png" alt="AskIf">
<p><b>AskIf</b><br/>
FINANCIAL</p>
<img src="/images/f28-pharma.png" alt="Cambscuisine">
<p><b>Cambscuisine</b><br/>
OTHER</p>
<img src="/images/f28-software.png" alt="Cyance">
<p><b>Cyance</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="Driftrock">
<p><b>Driftrock</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="Liopa">
<p><b>Liopa</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="Measurematch">
<p><b>Measurematch</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="infloAi">
<p><b>infloAi</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="Kulea">
<p><b>Kulea</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="Sensize">
<p><b>Sensize</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="2Mee">
<p><b>2Mee</b><br/>
SOFTWARE</p>
<p><b>Mayku</b><br/>
TECH</p>
<img src="/images/f28-technology.png" alt="Mimica">
<p><b>Mimica</b><br/>
TECH</p>
{% endfullWidth %}
The first Fund Twenty8 closed in 2017 and finished deploying in 2018. By September, the portfolio was valued at 108% (paper value). Its final portfolio is a testament to the fund''s mission: to deliver investors a large and diversified portfolio of at least 28 investments.
233 investors took part
Invested a total of £4.55m
Diversified over 32 investments
Across 10 sectors
{% button https://files.syndicateroom.com/guides/fund-twent8-2016-portfolio.pdf "Portfolio breakdown (PDF)" primary %}
<img src="/images/f28-engineering.png" alt="Dymag">
<p><b>Dymag</b><br/>
ENGINEERING</p>
<img src="/images/f28-environment.png" alt="Alert Technology">
<p><b>Alert Technology</b><br/>
ENVIRONMENT</p>
<img src="/images/f28-environment.png" alt="USIO">
<p><b>USIO</b><br/>
ENVIRONMENT</p>
<img src="/images/f28-marketplaces.png" alt="Pekama">
<p><b>Pekama</b><br/>
MARKETPLACES</p>
<img src="/images/f28-marketplaces.png" alt="Starstock">
<p><b>Starstock</b><br/>
MARKETPLACES</p>
<img src="/images/f28-marketplaces.png" alt="Celame">
<p><b>Celame</b><br/>
MARKETPLACES</p>
<img src="/images/f28-marketplaces.png" alt="Biotechspert">
<p><b>Biotechspert</b><br/>
MARKETPLACES</p>
<img src="/images/f28-marketplaces.png" alt="Make it Social">
<p><b>Make it Social</b><br/>
MARKETPLACES</p>
<img src="/images/f28-healthcare.png" alt="e-Patient Network">
<p><b>e-Patient Network</b><br/>
HEALTHCARE</p>
<img src="/images/f28-healthcare.png" alt="Dem DX">
<p><b>Dem DX</b><br/>
HEALTHCARE</p>
<img src="/images/f28-healthcare.png" alt="Emoquo">
<p><b>Emoquo</b><br/>
HEALTHCARE</p>
<img src="/images/f28-media.png" alt="SupaPass">
<p><b>SupaPass</b><br/>
MEDIA</p>
<img src="/images/f28-pharma.png" alt="Peptinnovate">
<p><b>Peptinnovate</b><br/>
PHARMA</p>
<img src="/images/f28-pharma.png" alt="Re-Vana Therapeutics">
<p><b>Re-Vana Therapeutics</b><br/>
PHARMA</p>
<img src="/images/f28-pharma.png" alt="Digital Therapeutics">
<p><b>Digital Therapeutics</b><br/>
PHARMA</p>
<img src="/images/f28-pharma.png" alt="Camallergy">
<p><b>Camallergy</b><br/>
PHARMA</p>
<img src="/images/f28-pharma.png" alt="Momentum Bioscience">
<p><b>Momentum Bioscience</b><br/>
PHARMA</p>
<img src="/images/f28-pharma.png" alt="FutureYou">
<p><b>FutureYou</b><br/>
PHARMA</p>
<img src="/images/f28-pharma.png" alt="Metrion Biosciences">
<p><b>Metrion Biosciences</b><br/>
PHARMA</p>
<img src="/images/f28-pharma.png" alt="Arcis">
<p><b>Arcis</b><br/>
PHARMA</p>
<img src="/images/f28-medtech.png" alt="Redecol">
<p><b>Redecol</b><br/>
MEDTECH</p>
<img src="/images/f28-software.png" alt="Warwick Analytics">
<p><b>Warwick Analytics</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="Articheck">
<p><b>Articheck</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="Brytlyt">
<p><b>Brytlyt</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="Fantoo">
<p><b>Fantoo</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="10to8">
<p><b>10to8</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="Cyance">
<p><b>Cyance</b><br/>
SOFTWARE</p>
<img src="/images/f28-software.png" alt="TenderSpace">
<p><b>TenderSpace</b><br/>
SOFTWARE</p>
<img src="/images/f28-technology.png" alt="Warwick Audio">
<p><b>Warwick Audio</b><br/>
TECH</p>
<img src="/images/f28-technology.png" alt="Freedom One">
<p><b>Freedom One</b><br/>
TECH</p>
<p><b>Shields Energy</b><br/>
TECH</p>
<img src="/images/f28-transport.png" alt="Engenie">
<p><b>Engenie</b><br/>
TRANSPORT</p>
{% endfullWidth %}